Dr.Reddy's Laboratories Ltd (NYSE:RDY) has earned a consensus recommendation of “Sell” from the six research firms that are covering the firm. Three research analysts have rated the stock with a sell rating and two have assigned a hold rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $41.90.
Separately, TheStreet cut shares of Dr.Reddy's Laboratories from a “b-” rating to a “c” rating in a research note on Monday, February 6th.
Dr.Reddy's Laboratories (NYSE:RDY) opened at 41.71 on Thursday. The stock’s 50 day moving average is $43.49 and its 200-day moving average is $45.57. The firm has a market capitalization of $6.91 billion, a PE ratio of 48.56 and a beta of 0.53. Dr.Reddy's Laboratories has a one year low of $39.65 and a one year high of $54.73.
Large investors have recently bought and sold shares of the stock. Alps Advisors Inc. raised its stake in Dr.Reddy's Laboratories by 1.0% in the third quarter. Alps Advisors Inc. now owns 7,097 shares of the company’s stock worth $329,000 after buying an additional 67 shares in the last quarter. Wetherby Asset Management Inc. raised its stake in Dr.Reddy's Laboratories by 4.9% in the fourth quarter. Wetherby Asset Management Inc. now owns 7,776 shares of the company’s stock worth $352,000 after buying an additional 366 shares in the last quarter. Creative Planning raised its stake in Dr.Reddy's Laboratories by 5.4% in the third quarter. Creative Planning now owns 8,443 shares of the company’s stock worth $392,000 after buying an additional 434 shares in the last quarter. GAM Holding AG raised its stake in Dr.Reddy's Laboratories by 0.6% in the third quarter. GAM Holding AG now owns 89,000 shares of the company’s stock worth $4,131,000 after buying an additional 500 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Dr.Reddy's Laboratories by 8.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,721 shares of the company’s stock worth $358,000 after buying an additional 592 shares in the last quarter. Institutional investors own 16.12% of the company’s stock.
Your IP Address:
Dr.Reddy's Laboratories Company Profile
Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).
Receive News & Ratings for Dr.Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories Ltd and related companies with MarketBeat.com's FREE daily email newsletter.